NCT01934335 2021-11-01
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
University of Iowa
Phase 2 Terminated
Clinical Trials
10 trialsNCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00459121 2019-03-26
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00745732 2018-11-14
Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00481845 2017-02-07
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
Stanford University
Phase 2 Terminated
NCT00290537 2016-05-19
Phase II Study of ZD6474 in Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00402896 2016-03-09
Malignant Pleural Effusion With ZD6474
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00683787 2015-01-08
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00533169 2011-12-15
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00732745 2011-08-22
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
Case Comprehensive Cancer Center
Phase 1 Terminated